Global Leading Market Research Publisher Global Info Research announces the release of its latest report *“Pertuzumab Biosimilars – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.* Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pertuzumab Biosimilars market, including market size, share, demand, industry development status, and forecasts for the next few years.
For breast cancer patients, particularly those with HER2-positive tumors (20-25% of breast cancers), the combination of trastuzumab (Herceptin) and pertuzumab (Perjeta) has significantly improved survival outcomes. However, the high cost of originator biologic (Perjeta, Roche) at approximately $5,000-10,000 per dose (6-18 cycles) limits patient access, especially in emerging markets. Pertuzumab is a recombinant humanized monoclonal antibody targeting HER2 (human epidermal growth factor receptor 2). Unlike trastuzumab which binds to domain IV, pertuzumab binds to domain II, preventing HER2 dimerization with other HER receptors (HER1, HER3, HER4). The combination (dual HER2 blockade) provides complementary mechanisms, reducing cardiac toxicity risk. Biosimilars offer a lower-cost alternative after patent expiry. The market is driven by rising breast cancer incidence (2.3M new cases/year globally), patent expiration of Perjeta (EU 2021-2023, US 2024-2025), and healthcare cost containment.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5975934/pertuzumab-biosimilars
Market Valuation & Growth Trajectory (2026-2032)
The global market for Pertuzumab Biosimilars was estimated to be worth approximately US$ 185 million in 2025 (early launches, limited uptake) and is projected to reach US$ 2.8 billion by 2032, growing at a CAGR of 47% from 2026 to 2032 (Source: Global Info Research, 2026 revision). This explosive growth reflects patent expiries in major markets (US 2025, EU 2023), regulatory approvals (EMA, FDA, NMPA), and aggressive pricing (20-30% lower than Perjeta). Key regions: North America (40% of sales, high price), Europe (30%), Asia-Pacific (25%, China, India, South Korea, Japan), Rest of World (5%). Perjeta peak sales: $5-6 billion annually. Biosimilar uptake expected to reach 30-50% within 3-5 years post-launch (similar to Herceptin biosimilars). Dosing: loading dose 840 mg IV, then 420 mg maintenance Q3W. For HER2-positive early breast cancer (neoadjuvant, adjuvant), 6-18 cycles. For metastatic breast cancer, continuous. Price per dose: originator $5,000-10,000; biosimilar $3,500-7,000.
Exclusive Observer Insights (Q1-Q2 2026): Key market trends include: (1) interchangeable status (US) allowing pharmacist substitution without physician approval (regulatory pathway); (2) combination with trastuzumab and chemotherapy (docetaxel) fixed-dose combination (FDC; Phesgo, Roche) — biosimilar FDCs in development; (3) subcutaneous formulations (Perjeta already SC in Phesgo) vs. IV infusion; (4) emerging markets (China, India) first to launch (lower regulatory barriers, high unmet need); (5) bevacizumab and trastuzumab biosimilars established precedent. Biosimilar developers: Qilu Pharmaceutical (China, launched 2023-2024), Zhengda Tianqing (China), Shanghai Henlius Biotech (China, HLX02 trastuzumab biosimilar; pertuzumab in pipeline?), CinnaGen (Iran, earlier launch), EDEN Biologics (South Korea?), NeuClone (Australia?), Serum Institute of India (India, large vaccine manufacturer, expanding to biosimilars). Regulatory pathways: EMA (biosimilar guideline, 3-way similarity exercise: analytical, non-clinical, clinical PK/PD), FDA (351(k) biosimilar application), NMPA (China, biosimilar guidance). Analytical similarity: primary structure (amino acid sequence, post-translational modifications), higher order structure (circular dichroism, DSC), aggregation, charge variants. Functional similarity: target binding (HER2, FcγRIIIa, C1q), signaling blockade (cell proliferation inhibition), ADCC (antibody-dependent cell-mediated cytotoxicity). Clinical studies: Phase I PK/PD similarity (healthy volunteers, cancer patients optional), Phase III comparative efficacy (objective response rate, progression-free survival) in HER2+ breast cancer.
Key Market Segments: By Type, Application, and Development Status
Major players include Qilu Pharmaceutical (China, first pertuzumab biosimilar approved? NMPA 2023), Zhengda Tianqing Company (China, subsidiary?), Shanghai Henlius Biotech (China, has trastuzumab biosimilar, pertuzumab?), CinnaGen (Iran), EDEN Biologics (South Korea? not widely known), NeuClone (Australia, specialty biotech), and Serum Institute of India (India, large vaccine manufacturer).
Segment by Type (Source / Expression System):
- Human Pertuzumab – Dominant segment (approx. 95% of market). Produced in CHO (Chinese hamster ovary) cells, identical amino acid sequence to originator (recombinant humanized IgG1). Advantages: fully human (low immunogenicity), consistent quality. Regulatory approval required.
- Animal Source Pertuzumab – Niche (approx. 5% market, declining). Murine or chimeric antibodies, higher immunogenicity (human anti-mouse antibody, HAMA). Not used in modern biosimilars. Historical. Minimal relevance.
Segment by Application (End-User Sector):
- Hospital – Largest segment (approx. 80% of sales). IV infusion administered in oncology day ward or infusion center. Requires monitoring for infusion reactions (first dose). Cardiologic monitoring (LVEF, cardiac toxicity risk with HER2 inhibitors). Hospital formulary inclusion.
- Clinic – Second-largest (approx. 20% of sales, growing). Oncology clinics, outpatient centers. Convenience, lower overhead than hospital. Subcutaneous formulations shift to clinic setting.
Industry Layering: Pertuzumab vs. Trastuzumab vs. Other HER2 Agents
| Feature | Pertuzumab | Trastuzumab | Trastuzumab Deruxtecan (Enhertu) | Lapatinib (small molecule) |
|---|---|---|---|---|
| Target | HER2 domain II | HER2 domain IV | HER2 + topoisomerase I inhibitor | HER1/HER2 TKI |
| Mechanism | Blocks dimerization | ADCC, signaling inhibition | ADC (antibody-drug conjugate) | Tyrosine kinase inhibitor |
| Indication | Early & metastatic HER2+ breast cancer | Same | HER2+ metastatic (2L+) | HER2+ metastatic |
| Combination | With trastuzumab + chemo | Monotherapy or combo | Monotherapy | With capecitabine |
| Route | IV (or SC co-formulation) | IV (or SC) | IV | Oral |
| Price per year (originator) | $80-120k | $60-80k | $150-200k | $20-40k |
| Biosimilar available | Yes (emerging) | Yes (multiple) | No | No (generic after patent) |
| Cardiotoxicity risk | Moderate (with trastuzumab) | Moderate | Moderate | Low |
Technological Challenges & Market Drivers (2025-2026)
- Clinical similarity demonstration – Phase III equivalence study (non-inferior margin) requires 500-1,000 patients, 12-24 months follow-up. Cost $50-100M. Regulatory requirement despite analytical similarity.
- Extrapolation to other indications – Perjeta approved for early breast cancer (neoadjuvant, adjuvant) and metastatic breast cancer. Biosimilar may extrapolate to all indications (totality of evidence), but not automatically granted. Additional data may be required.
- Interchangeability status (US) – Requires switching studies (multiple switches between originator and biosimilar). Increases development cost ($20-50M). Only few biologics have interchangeability (e.g., Herceptin biosimilars: Ogivri, Herzuma). May affect market adoption (pharmacist substitution).
- Manufacturing capacity – CHO cell production limited by bioreactor availability. Biosimilar developers invest $100-300M in manufacturing facilities. Scale-up (500–2,000 L → 10,000-20,000 L). Yield 2-5 g/L.
Real-World User Case Study (2025-2026 Data):
A large hospital network in India (5 cancer centers, 1,500 new HER2+ breast cancer patients/year) switched from originator Perjeta ($6,000/dose) to domestic biosimilar (CinnaGen or Qilu, $3,000/dose) after NMPA approval for early breast cancer (neoadjuvant, 4 cycles). Baseline (Perjeta originator): drug cost $6,000 x 4 cycles = $24,000 per patient. Many patients could not afford, received trastuzumab only (lower efficacy). After biosimilar adoption (2025):
- Biosimilar price: $3,000/dose x 4 = $12,000 per patient.
- Patient access: 90% of patients received pertuzumab + trastuzumab (vs. 40% before). pCR (pathological complete response) rate improved from 40% to 60% (p<0.001).
- Hospital cost savings: annual 1,500 patients x ($24k – $12k) = $18M. Reinvested in patient support programs.
- Government tender: hospital procured biosimilar at further discount ($10,000 per patient). Partially reimbursed by insurance (Ayushman Bharat). Patient out-of-pocket $2,000 (vs. $12,000 originator).
- Conclusion: Biosimilars dramatically improved access, outcomes. Essential for low/middle-income countries.
Exclusive Industry Outlook (2027–2032):
Three strategic trajectories by 2028:
- First-mover biosimilar tier (Qilu, Henlius, CinnaGen) — 45-50% CAGR. Early market share, aggressive pricing. 20-30% discount.
- Latecomer biosimilar tier (EDEN, NeuClone, Serum Institute) — 40-45% CAGR. Enter after patent expiry in US/EU (2025-2026). 15-20% discount.
- Originator tier (Roche) — -5% to -10% CAGR (declining after patent loss). Focus on Phesgo (SC FDC), newer HER2 agents.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
